SAR 438151Alternative Names: SAR438151
Latest Information Update: 11 May 2016
At a glance
- Originator Sanofi
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 30 Apr 2016 Discontinued - Phase-I for Undefined indication in France (unspecified route)
- 01 Aug 2013 Phase-I clinical trials in Undefined indication in France (unspecified route)